01 Expanding Clinical Applications beyond Atrial Fibrillation Pulsed field ablation (PFA), originally developed for treating atrial fibrillation (AF), is now being explored for other arrhythmias, such as ventricular tachycardia. Recent studies have highlighted PFA’s ability to precisely target arrhythmogenic tissue in the ventricles while minimizing damage to surrounding structures, making it a promising treatment for various heart conditions. For example, in April 2024, Thermedical conducted a feasibility study combining PFA with its SERF Ablation System and Durablate Catheter, demonstrating its potential in treating ventricular tachycardia. Thus, expanding clinical applications beyond atrial fibrillation plays a crucial role in increasing demand for pulsed field ablation technology.
02 Integration with Electrophysiology Mapping Systems The integration of PFA technology with cutting-edge electrophysiology mapping systems enhances the precision, safety, and effectiveness of ablation procedures. By enabling real-time visualization, these systems offer invaluable feedback during procedures. For instance, in January 2024, Biosense Webster, Inc., a part of Johnson & Johnson, received regulatory clearance in Japan for its VARIPULSE PFA platform, which integrates with the CARTO 3 System. This integrated system streamlines workflows and improves outcomes, making PFA even more effective and reliable for treating AF.
June 2026 Medtronic received U.S. FDA approval for an expanded indication of the PulseSelect Pulsed Field Ablation System, enabling treatment of additional atrial fibrillation patient populations and strengthening its electrophysiology portfolio.
May 2026 Abbott announced positive pivotal clinical results from its VOLT-AF trial supporting the safety and effectiveness of its Volt Pulsed Field Ablation System, advancing global regulatory submissions and commercialization plans.
March 2026 Kardium initiated expanded commercial deployment of its Globe Pulsed Field System across selected European electrophysiology centers following continued clinical adoption and physician training programs.
November 2025 Johnson & Johnson MedTech presented new clinical and real-world evidence for its VARIPULSE Pulsed Field Ablation Platform at major electrophysiology congresses, reinforcing the platform’s safety, efficacy, and procedural workflow advantages.
September 2025 Boston Scientific expanded the commercial availability of its FARAPULSE Pulsed Field Ablation System into additional international markets following increased regulatory clearances and growing physician adoption for atrial fibrillation treatment.